Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Act-HIB + ViscoGel
- Development stage
- Unknown
- Lead developer
- Viscogel
- Modality
- Hydrogel Systems → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Act-HIB + ViscoGel is an investigational vaccine formulation that combines the commercially available Haemophilus influenzae type b (Hib) conjugate vaccine, Act-HIB, with the ViscoGel adjuvant system. ViscoGel is a proprietary chitosan-based hydrogel adjuvant developed by Viscogel AB, composed of the chitosan derivative Viscosan (50% degree of deacetylation) processed into gel particles. Act-HIB consists of Hib capsular polysaccharide (polyribosylribitol phosphate) conjugated to a tetanus toxoid carrier protein. The ViscoGel adjuvant functions as an immunostimulatory delivery vehicle designed to enhance both humoral and cellular immune responses, specifically increasing interferon-gamma production compared to non-adjuvanted vaccines. This combination is intended for the prevention of Hib infections, which are significant causes of bacterial meningitis and pneumonia in children. It has been evaluated in a Phase I/IIa clinical trial (NCT01578070) where it demonstrated safety and enhanced immunogenicity.
- Brand names
- Act-HIBViscoGel
- Other names
- ViscoGel and Act-HIB vaccineViscoGel-adjuvanted Act-HIB
02
Targets
TT (Tetanus toxoid)
Beyond the preview
Go deeper on Act-HIB + ViscoGel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Act-HIB + ViscoGel.